Last updated: February 9, 2026
Litigation Summary and Analysis: Avanir Pharmaceuticals Inc. v. Watson Pharmaceuticals Inc. | 1:12-cv-00258
Case Overview
Avanir Pharmaceuticals Inc. filed patent infringement suits against Watson Pharmaceuticals Inc. in the District of Delaware in 2012, alleging that Watson's generic versions of its drug, Nuedexta (dextromethorphan/quinidine), infringed on Avanir’s U.S. Patent No. 7,659,190 (the '190 patent). The case involves claims seeking injunctive relief and monetary damages.
Patent Details
- Patent Title: Method of treating pseudobulbar affect
- Patent Number: 7,659,190
- Filing Date: Priority date 2005
- Expiration: Expected in 2026
Key Allegations
- Watson's generic products directly infringe upon the '190 patent.
- Watson's submission of an Abbreviated New Drug Application (ANDA) constitutes an act of patent infringement under 35 U.S.C. § 271(e)(2).
Procedural Timeline
- 2012: Complaint filed by Avanir.
- 2012–2013: Litigation period, with motions to dismiss and preliminary injunction considerations.
- 2013: FDA approval granted for Watson’s ANDA, indicating infringement concerns.
- 2014: Court proceedings focus on validity and infringement issues.
- 2015: Settlement discussions, with eventual resolution outside of court.
Court Rulings and Outcomes
- The case did not proceed to a final judgment on the infringement or validity of the patent.
- Instead, Avanir and Watson entered into a settlement agreement in 2015, which included a license agreement allowing Watson to market its generic version after the patent's expiration.
Analysis and Impact
- The litigation highlights the strategic importance of biotech patents covering method-of-treatment claims.
- The resolution via settlement is common in patent litigation involving pharmaceuticals, especially once generic approval is imminent.
- The '190 patent's life extends until 2026, making infringement suits a critical tool for Avanir to delay generic entry.
Market and R&D Implications
- The case underscores the significance of patent protection in extending commercial exclusivity.
- The settlement aligns with industry trends favoring licensing over prolonged litigation.
- The dispute showcases the interplay between innovative drug patents and the generic pathway.
Regulatory Considerations
- The ANDA process under the Hatch-Waxman Act facilitated the litigation.
- Federal courts routinely handle patent disputes at the intersection of drug approval and patent rights.
Strategic Takeaways
- Patent litigation remains a key component of pharmaceutical product lifecycle management.
- Settlements can provide strategic value in controlling market entry timing.
- Patent strength, especially on method-of-treatment claims, influences litigation and licensing strategies.
Key Takeaways
- The Avanir-Watson case centered on patent rights for a method of treating pseudobulbar affect.
- The case was resolved through a licensing settlement in 2015, prior to a final court decision.
- Patent validity and enforceability remain contested issues, but settlements often avoid protracted litigation.
- The case illustrates how patent protections influence generic drug market entry.
- Litigation outcomes impact drug availability, market competition, and R&D investments.
Frequently Asked Questions
Q1: Did the case establish any precedents regarding method-of-treatment patents?
Q2: Can patent infringement suits delay generic drug entry?
Yes. Litigation or settlement agreements can extend exclusivity or delay approval of generics.
Q3: How typical is settlement rather than a court ruling in pharmaceutical patent disputes?
Very common. Over 80% of patent disputes lead to settlement agreements.
Q4: What strategies does Avanir likely pursue after settlement?
Focus on patent enforcement, licenses, or additional patent filings to protect market share.
Q5: Could Watson's generic launch have proceeded earlier without settlement?
Potentially, if the court invalidated the patent or the case was dismissed; however, risk of infringement liability would remain.
References
[1] U.S. District Court, District of Delaware, Case No. 1:12-cv-00258.
